NeoRx: NeuroVir's replicating vectors

With the acquisition of NeuroVir Therapeutics Inc. last week, MediGene AG has picked up a technology platform for production of herpes simplex virus (HSV) vectors and two products in the clinic. The HSV technology complements MediGene's existing vector platform using adeno-associated virus (AAV).

"The principle difference between our technology and others developing HSV vectors is that we use replicating viruses," according to Frank Tufaro, CEO of NeuroVir (San Diego, Calif.)...